UOB Kay Hian lifted its target price for Lijun International (02005) to HK$5 from HK$4.3, and maintained its "buy" call.
The research house Lijun's 1H results are better. It expects the gradual opening of drug tenders to offer great market expansion opportunities for Lijun. By focusing on
increasing the revenue contribution of higher-margin therapeutic infusion products in the next few years, its margin is likely to improve further, said UOBKH.
Moreover, it said the company has disposed of Xi'an Lijun and launched new business strategies for sustainable growth in the longer term.
02/09/2014 17:25
{BLOCK TRADE}UOBKH lifts Lijun Int'l (02005) to HK$5
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
